Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic User Fee Transition A Little Bumpy For Contract Manufacturers

Executive Summary

Problems with self-identification process caused by timing of legislative renewal may have affected figures used by US FDA to calculate FY 2018 GDUFA fees.

Advertisement

Related Content

Inside The ANDA Parking Lot
Inside The ANDA Parking Lot
US FDA Changes Data Source For GDUFA II Facility Fee Setting
Generic User Fee Hikes Could Disrupt US FDA Drug Pricing Campaign
Generic Drug Sponsors Seek Advance Notice Of Approvals From US FDA
GDUFA II: ANDAs, Not Facilities Will Govern Revenue
ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal
ANDA Communication Complaints: FDA Takes Licking, Keeps Ticking

Topics

Advertisement
UsernamePublicRestriction

Register

PS121871

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel